Literature DB >> 15692338

Development of a tissue array for primary melanoma with long-term follow-up: discovering melanoma cell adhesion molecule as an important prognostic marker.

Marc D Pacifico1, Rajiv Grover, Paul I Richman, Frances M Daley, Francesca Buffa, George D Wilson.   

Abstract

Refining current prognostic capability is essential for improving the management of melanoma. This study was undertaken to develop a tumor array for the rapid assessment of novel prognostic markers in a series of specimens from melanoma patients with 7- to 10-year follow-up. A melanoma database of 120 patients with archival specimens was created after histopathological review of original specimens. A tissue array was developed allowing 480 biopsy samples from the 120 primary melanoma specimens to be embedded into a single paraffin block. This was sectioned and stained for the adhesion marker melanoma cell adhesion molecule (MCAM); after further review, 76 of the 120 specimens were suitable for further analysis. The slides were assessed by two independent observers without previous knowledge of the clinical outcome for staining positivity and stain intensity. Assessment of association between MCAM and clinicopathological features was carried out using chi-squared analysis, and univariate and Cox multivariate analyses were performed on the data. There was a high correlation between MCAM intensity and both Clark's level and Breslow thickness (Spearman correlation p < 0.001 for both). The data revealed that MACM was a highly specific prognostic marker for survival in univariate analysis (chi2 = 18, p < 0.0001). Subgroup analysis by stratification of the staining intensity revealed a sequentially worsening survival with increasing staining intensity (chi2 = 22.33, p < 0.0001). Multivariate analysis of survival showed MCAM to be an independent prognostic marker more accurate than all other clinicopathological parameters (p < 0.0001), including the Breslow depth. Further analysis within only intermediate-thickness tumors showed MCAM intensity added further refinement to outcome prediction (chi2 = 22.33, p < 0.0001). The tissue array provided a rapid method of analyzing up to 480 specimens within a single paraffin block. This will benefit many areas of plastic surgery research. The identification of adhesion markers revealed a valuable prognostic marker for predicting outcome and a potential target for therapeutic manipulation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15692338     DOI: 10.1097/01.prs.0000148417.86768.c9

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  22 in total

1.  Melanoma prognostic model using tissue microarrays and genetic algorithms.

Authors:  Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

2.  ZBTB7A Suppresses Melanoma Metastasis by Transcriptionally Repressing MCAM.

Authors:  Xue-Song Liu; Matthew D Genet; Jenna E Haines; Elie K Mehanna; Shaowei Wu; Hung-I Harry Chen; Yidong Chen; Abrar A Qureshi; Jiali Han; Xiang Chen; David E Fisher; Pier Paolo Pandolfi; Zhi-Min Yuan
Journal:  Mol Cancer Res       Date:  2015-05-20       Impact factor: 5.852

3.  Gene expression profile of B 16(F10) murine melanoma cells exposed to hypoxic conditions in vitro.

Authors:  Magdalena Olbryt; Michał Jarzab; Joanna Jazowiecka-Rakus; Krzysztof Simek; Stanisław Szala; Aleksander Sochanik
Journal:  Gene Expr       Date:  2006

Review 4.  Biomarkers Predictive of Survival and Response to Immune Checkpoint Inhibitors in Melanoma.

Authors:  Emanuelle M Rizk; Angelina M Seffens; Megan H Trager; Michael R Moore; Larisa J Geskin; Robyn D Gartrell-Corrado; Winston Wong; Yvonne M Saenger
Journal:  Am J Clin Dermatol       Date:  2020-02       Impact factor: 7.403

Review 5.  Construction and analysis of multiparameter prognostic models for melanoma outcome.

Authors:  Bonnie E Gould Rothberg; David L Rimm
Journal:  Methods Mol Biol       Date:  2014

Review 6.  Tissue prognostic biomarkers in primary cutaneous melanoma.

Authors:  Mario Mandalà; Daniela Massi
Journal:  Virchows Arch       Date:  2014-02-01       Impact factor: 4.064

7.  PAX3 expression in normal skin melanocytes and melanocytic lesions (naevi and melanomas).

Authors:  Sandra Medic; Mel Ziman
Journal:  PLoS One       Date:  2010-04-22       Impact factor: 3.240

8.  Identification of MCAM/CD146 as the target antigen of a human monoclonal antibody that recognizes both epithelioid and sarcomatoid types of mesothelioma.

Authors:  Scott Bidlingmaier; Jiang He; Yong Wang; Feng An; Jinjin Feng; Dario Barbone; Dongwei Gao; Ben Franc; V Courtney Broaddus; Bin Liu
Journal:  Cancer Res       Date:  2009-02-03       Impact factor: 12.701

Review 9.  Melanoma biomarkers: current status and vision for the future.

Authors:  Allison R Larson; Eliz Konat; Rhoda M Alani
Journal:  Nat Clin Pract Oncol       Date:  2008-12-23

10.  Expression and distribution of MUC18 in human uveal melanoma.

Authors:  Kenneth Lai; Vidushi Sharma; Martine J Jager; R Max Conway; Michele C Madigan
Journal:  Virchows Arch       Date:  2007-09-05       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.